Home › Trial NCT05789667
Gender-based Impact on Safety and Efficacy of Lenvatinib in Patients With Differentiated Thyroid Cancer
- Trial IDNCT05789667
- StatusCompleted
- PhaseN/A
- Study typeObservational
- SponsorRegina Elena Cancer Institute
- Enrollment138
- Start date2020-05-27
- ConditionsDifferentiated Thyroid Cancer · Gender
Enriched analysis
Parsed endpoints, structured eligibility, drug class and a plain-English summary — shown to verified visitors to prevent automated scraping.
Trial data from ClinicalTrials.gov (U.S. public domain) and ISRCTN (CC BY 4.0), used with attribution. TrialLens is an independent index, not affiliated with or endorsed by ClinicalTrials.gov, the NIH, or any trial sponsor. For research only — not medical advice.